192505-56-9

Upstream product

• 19488-48-3 methyl O-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 200712-59-0 C₃₆H₄₄O₁₂ 
• 100-39-0 benzyl bromide 
• 200712-61-4 methyl (6-O-tert-butyldimethylsilyl-4-O-levulinyl-2,3-di-O-methyl-α-L-idopyranosyl)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 200712-62-5 (2R,3S,4S,5R,6R)-6-((2R,3R,4S,5R,6S)-4,5-Bis-benzyloxy-2-benzyloxymethyl-6-methoxy-tetrahydro-pyran-3-yloxy)-4,5-dimethoxy-3-(4-oxo-pentanoyloxy)-tetrahydro-pyran-2-carboxylic acid 
• 200712-56-7 methyl(2-O-benzoyl-4,6-O-isopropylidene-3-O-methyl-α-L-idopyranosyl)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 200712-63-6 methyl (benzyl 4-O-levulinyl-2,3-di-O-methyl-α-L-idopyranosyluronate)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 200712-60-3 (2S,3R,4S,5R,6S)-6-((2R,3R,4S,5R,6S)-4,5-Bis-benzyloxy-2-benzyloxymethyl-6-methoxy-tetrahydro-pyran-3-yloxy)-2-(tert-butyl-dimethyl-silanyloxymethyl)-4,5-dimethoxy-tetrahydro-pyran-3-ol 
• 162610-20-0 methyl(4,6-O-isopropylidene-3-O-methyl-α-L-idopyranosyl)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 200712-57-8 methyl(4,6-O-isopropylidene-2,3-di-O-methyl-α-L-idopyranosyl)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 200712-58-9 methyl(2,3-di-O-methyl-α-L-idopyranosyl)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 

Downstream Products

• 200712-67-0 methyl (benzyl 4-O-levulinyl-2,3-di-O-methyl-α-L-idopyranosyluronate)-(1->4)-(3,6-di-O-acetyl-2-O-benzyl-α-D-glucopyranosyl)-(1->4)-(benzyl 2,3-di-O-methyl-α-L-idopyranosyluronate)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 200712-73-8 (benzyl 2,3-di-O-methyl-α-L-idopyranosyluronate)-(1->4)-1,3,6-tri-O-acetyl-2-O-benzyl-D-glucopyranose 
• 1186009-11-9 C₁₀₁H₁₁₈O₂₈ 
• 200712-71-6 methyl(benzyl 4-O-chloroacetyl-2,3-di-O-methyl-α-L-idopyranosyluronate)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 

Relevant academic research and scientific papers

Efficient synthesis of Idraparinux, the anticoagulant pentasaccharide

An efficient [DEF+GH] route was developed to the synthesis of Idraparinux, which is a fully O-sulfated, O-methylated mimic of the unique Antithrombin III binding domain of heparin.

Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerisation'

Three hexasaccharides, having from low to very high affinity for antithrombin, were synthesised from disaccharide building block precursors. One of them, methyl(sodium 2,3-di-O-methyl-4-O-sodium sulfonato-α-L-idopyranosyluronate)-(1→4)-[(2,3,6-tri-O-sodium sulfonato-α-D-glucopyranosyl)-(1→4)-(sodium 2,3-di-O-methyl-α-L-idopyranosyluronate)-(1→4)]2-2,3,6-tri-O-sodium sulfonato-α-D-glucopyranoside, obtainable from a single disaccharide building block precursor, constitutes a good starting point for obtaining simple oligosaccharidic heparin mimetics able to inhibit the two coagulation factors thrombin and Factor Xa. Copyright (C) 1999 Elsevier Science Ltd.

First synthetic carbohydrates with the full anticoagulant properties of heparin

A single disaccharide building block is required to obtain synthetic carbohydrates that reproduce the anticoagulant activity of heparin and inhibit thrombin (n > 6) and/or factor Xa (n ≥ 2; see reaction scheme). Thus, there is evidence that heparin fragme